Introduction
============

Chronic heart failure (CHF) is the leading cause of mortality in most developed countries ([@b9]). The prevalence and mortality rates of CHF used to be relatively lower in Japan compared with other Western countries. In Japan, approximately 1 to 2 million patients have CHF and nearly 170,000 patients die due to heart diseases each year (approximately 130 per 100,000 person-years) ([@b23]). However, the prevalence and death rates of cardiovascular diseases and CHF have been rapidly increasing in Japan, due to the Westernization of lifestyle, including dietary habits, and the aging population (The Status of Aging 2007). The Chronic Heart Failure Analysis and Registry in the Tohoku District (CHART)-1 study was one of the largest cohort studies with Japanese CHF patients (N = 1,278), which was designed to evaluate the characteristics and prognosis of those patients. We have also started a new cohort study, named the CHART-2 study (N = 10,000, expected) aiming to elucidate the effective preventive measures for CHF. This review briefly summarizes the major socio-medical issues of Japanese patients with CHF, their clinical characteristics and prognosis found in our CHART-1 study, and the current status of CHF studies in Japan.

Socio-medical status of Japanese patients with CHF
==================================================

Rapid aging of Japanese population
----------------------------------

Until the 1980s, Japan had a lower percentage of elderly citizens compared with any other developed countries. However Japan is now one of the countries in which the population is aging rapidly. [Figure 1](#fig1){ref-type="fig"} shows the time-course of aging and population projections between 1950 and 2055, which is assembled using the data reported by the Japanese Cabinet Office (The Status of Aging 2007). As of October 1, 2006, the total population of Japan was 127.8 million and the number of elderly aged 65 or older was 26.6 million, accounting for 21% of the total population. The elderly population is expected to continue to increase rapidly and the percentage of the elderly will reach 35.8 million (27%) in 2055 (The Status of Aging 2007). Life expectancy in Japan at birth has also drastically increased since World War II to 78.6 years for males and 85.5 years for females in 2005 (Life Expectancies at Specified Ages 2006). The Japanese Cabinet Office expects that it will reach 83.7 years for males and 90.3 years for female in 2055. Thus, in the near future, Japanese society will encounter more difficult medical problems due to rapid aging, which other developed countries have never before experienced.

![Time-course and future prediction of the increase in elderly population and heart-disease mortality in Japan. Data are based on the Status of Aging and Implementation of Measures for Aging Society in 2005, reported by the Japanese Cabinet.](vhrm0401-103-01){#fig1}

Changing causes of death in Japan
---------------------------------

Infectious diseases such as pneumonia, tuberculosis, and gastroenteritis were the leading causes of death in Japan until the mid 1900s. The major health problems in Japanese society have drastically changed since World War II. The morbidity and mortality rates of lifestyle-related diseases such as cancer, heart disease, stroke, and diabetes mellitus have dramatically increased. Approximately 60% of the mortality is now attributed to lifestyle-related diseases (cancer, 31%; ischemic heart disease 16%; cerebrovascular disease 13%; diabetes mellitus 1%; and hypertensive disease 0.6%) and the medical costs for these diseases amounts to 10.2 trillion yen (87.8 billion US dollars), accounting for approximately 30% of the total cost of the Japanese health insurance in 2003 ([@b5]). Currently, heart disease is the second most frequent cause of death in Japan. [Figure 1](#fig1){ref-type="fig"} shows the trend of the mortality due to heart diseases, which is constructed using the reports of death certificates in Japan ([@b23]). There is a clear trend for the increase in death due to heart disease since 1950s (there was a temporary sharp decline in 1995 due to the tenth revision of the International Classification of Diseases regarding the description of diagnosis in death certificates).

Health insurance system and future economic burden in Japan
-----------------------------------------------------------

In Japan, all citizens are enrolled in the mandatory health insurance system based on employment and residential status. The average number of visits to a doctor per year is 16 in Japan, versus 5.8 visits in the United States ([@b10]). As elderly patients tend to visit doctors more frequently and to have more medication or high-cost medical care, medical expenditure for the elderly is already taking one-third of the national health expenditure, and is projected to reach a half of the expenditure by the year 2025 ([@b10]). Progressive aging of the society and the consequent increase in the number of patients with CHF will cause more financial burden within Japanese society, which could lower the quality of medical services in the future.

An overview of heart failure studies in Japan
=============================================

In Japan, medical treatment for patients with CHF is mainly based on the evidence obtained from randomized trials in the United States and Europe. There have been no sufficient randomized treatment trials or prospective cohort studies in Japan to clarify the real characteristics of Japanese patients with CHF or to improve their prognosis and quality of life. The mandatory health insurance system, the shortage of the budget to fulfill mega-trials, and the absence of trained research nurse system may all be responsible for the current situation. This section describes several cohort studies with Japanese CHF patients, major outcomes of the CHART-1 study, and randomized treatment trials for CHF performed with Japanese patients, either those that have already been published or are currently in progress. Finally, racial differences will be discussed, because this issue may also influence the impact of risk factors and/or the effects of treatments for CHF.

Prospective cohort studies in Japan
-----------------------------------

There are few multi-institutional prospective cohort studies with CHF patients in Japan ([Table 1](#tbl1){ref-type="table"}). The Chronic Heart Failure Analysis and Registry in the Tohoku District (CHART)-1 study was the first cohort study in Japan, including more than 1,000 Japanese patients with stable CHF, who were registered at 26 hospitals in the Tohoku district with a population of approximately 9.8 million ([@b20]). The CHART-1 study was initiated in February 2000 and was completed in December 2005. The total number of CHF patients enrolled was 1,278 and the mean follow-up period was 3.5 years. Details of design and the main outcome will be presented at the following part in this article. The Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD) is a registry of hospitalized patients with worsening CHF at 164 hospitals throughout the country between January 2004 and June 2005 ([@b26]). Death and hospital admission of the patients were followed through 2006 with the mean follow-up period of at least 1 year. Results of this study will appear in the near future. The Japanese Cardiac Registry of Heart Failure in General Practice (JCARE-GENERAL) is a registry of outpatients with CHF managed by cardiologists in hospitals and primary care physicians in general practice ([@b27]). Baseline data of totally 2,685 patients were collected during November 2004 and follow-up data were collected for 1 year after the enrolment. During the mean follow-up period of 427 days, the crude mortality rate was 6.7% in patients managed by cardiologists and 5.9% in those managed by general physicians. The Chronic Heart Failure Analysis and Registry in the Tohoku District (CHART)-2 study is currently the largest prospective and hospital-based cohort study with patients with CHF in Japan. This study was designed to investigate the characteristics and prognosis of a total of 10,000 patients with symptomatic CHF (Stage C/D in the ACC/AHA classification) and those with structural heart disease but without signs or symptoms of CHF (Stage-B in the AHA/ACC classification) ([@b9]). This study will elucidate the incidence and prognostic impact of metabolic syndrome in those patients, especially on the development of the first symptomatic CHF. The CHART-2 study was started in October 2006 and will be completed in September 2011.

###### 

Multicenter prospective cohort study for patients with chronic heart failure in Japan

  Study \[Reference\]        Study population                                                                   Age, years (Mean)   Total enrollment   Heart failure stage/NYHA   Study start Expected completion   Mean follow-up      1-year mortality   Status
  -------------------------- ---------------------------------------------------------------------------------- ------------------- ------------------ -------------------------- --------------------------------- ------------------- ------------------ ------------
  CHART-1 Study \[[@b20]\]   Chronic heart failure outpatients/ hospitalized pts.                               ≥18 (68)            1278               \(B\) C-D I-IV                                               3.5 years           7.3%               Published
  JCARE-CARD \[[@b26]\]      Hospitalized patients with heart failure                                           ≥15                 2676               C-D                                                          At least one year                      Completed
  JCARE-GENERAL \[[@b27]\]   Outpatients with heart failure                                                     ≥15 (74)            2685               C-D                                                          One year            6.3%               Published
  CHART-2 Study              Chronic heart failure High risk for heart failure outpatients/ hospitalized pts.   ≥20                 10000 (expected)   B-D I-IV                   Oct 2006 Sep 2011                                                        Recruiting

Data are retrieved from published papers or the UMIN Clinical Trials Registry (<http://www.umin.ac.jp/ctr/index-j.htm>)/ClinicalTrials.gov (<http://clinicaltrials.gov/>).

**Abbreviations:** NYHA, New York Heart Association; pts, patients.

The CHART-1 Study
=================

Risk stratification is the first line strategy to improve the prognosis and quality of life of patients with CHF. A number of factors have been found to correlate with the mortality of patients with CHF ([@b19]; [@b4]; [@b3]). The CHART-1 study was started to register patients with stable CHF in February 2000 to clarify the characteristics and prognosis and to seek for prognostic factors in Japanese CHF patients ([@b20], [@b21]). Patients were enrolled when at least one of the following criteria was met: (1) left ventricular ejection fraction (LVEF) \<50%, (2) left ventricular end-diastolic dimension \>55 mm, or (3) at least one episode of congestive heart failure. Patients less than 18 years old or those with clinically unstable conditions were excluded. Baseline data, including laboratory findings, results of echocardiography, and medical treatments for CHF, were recorded and annual surveillance was performed until the end of 2005.

Characteristics and prognosis of patients with CHF in Japan
-----------------------------------------------------------

A total of 1,278 patients were enrolled in the CHART-1 cohort. The mean age of the study population was 68.3 years, and male accounted for 66% of the total study population. The prevalence of diabetes mellitus and hypertension was 19% and 47%, respectively. Other baseline characteristics of patients are shown in [Table 2](#tbl2){ref-type="table"}. Ischemic etiology accounted for only 25% and the percentage of patients older than 65 years was 66%. Patients with preserved systolic function (defined as LVEF \>50%) accounted for 45% of the total population. During the mean follow-up period of 3.5 years, all-cause mortality rate at 1-, 2-, and 3-year was 7%, 16%, and 22%, respectively ([Figure 2](#fig2){ref-type="fig"}). Multivariate Cox analysis showed that several covariates, such as age, diabetes mellitus, ventricular tachycardia, serum level of B-type natriuretic peptide (BNP), rural residence, and NYHA functional class, were significantly associated with all-cause mortality ([@b20]). [Figure 3](#fig3){ref-type="fig"} shows the Kaplan-Meier analyses of freedom from all-cause mortality in patients stratified by serum level of BNP or LVEF. Patients with higher BNP concentration had a significantly poorer prognosis ([@b29]), however, the prognostic impact was not significantly different between patients with 200--500 pg/mL of BNP level and those with \>500 pg/mL ([Figure 3A](#fig3){ref-type="fig"}). The all-cause mortality of patients with preserved systolic function (LVEF \> 50%) was not significantly different than that of patients with moderately decreased LVEF (30%--50%). However the prognosis of those with severely low LVEF (\<30%) was the lowest with frequent episodes of sudden cardiac death ([Figure 3B](#fig3){ref-type="fig"}). The 3-year incidence of sudden death was higher in patients with LVEF \<30% than those with LVEF ≥30% (15% vs 4%, respectively, p \< 0.001). Primary prevention of sudden cardiac death with an implantable cardioverter defibrillator in those patients should be recommended when they meet the criteria in the authorized guidelines ([@b30]). Recently, anemia has been emphasized as an important prognostic predictor in patients with CHF ([@b6]). Our data also showed that anemia was significantly associated with all-cause mortality, cardiac-cause mortality, and sudden death in patients with diastolic CHF ([@b24]), as well as in those with systolic CHF, as reported by other researchers ([@b17]).

![Prognosis of the Japanese patients with CHF in the CHART-1 study. Copyright © 2004. Reproduced with permission from [@b20]. Analysis of chronic heart failure registry in the Tohoku district: third year follow-up. *Circ J*, 68:427--34.\
**Abbreviations:** HF, heart failure.](vhrm0401-103-02){#fig2}

![Kaplan-Meier curves of freedom from all-cause death stratified by (**A**) BNP and (**B**) LVEF in the CHART-1 study.\
**Abbreviations:** BNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction.](vhrm0401-103-03){#fig3}

###### 

Baseline characteristics of the Japanese patients in the CHART-1 study

  ---------------------------------------- -------------
  No. of patients                          1,278
  Follow-up period (years)                 3.5 ± 1.7
  Age (years)                              68.3 ± 13.4
   ≤39                                     3.7%
   40--64                                  30.2%
   65--74                                  32.8%
   ≥75                                     33.3%
  Male (%)                                 66.0%
  NYHA                                     
   I                                       19.7%
   II                                      63.0%
   III                                     16.5%
   IV                                      0.8%
  Underlying disease                       
   Coronary artery disease                 25.4%
   Valvular heart disease                  26.4%
   Left ventricular hypertrophy            14.0%
   Non-ischemic cardiomyopathy             28.6%
   Other                                   5.6%
  Left ventricular ejection fraction (%)   51.1 ± 15.9
   \<30%                                   11.7%
   30--50%                                 43.7%
   \>50%                                   44.6%
  Hypertension                             47.4%
  Diabetes                                 18.9%
  Dyslipidemia                             16.7%
  Atrial fibrillation                      41.8%
  Ventricular tachycardia                  20.1%
  History of heart failure admission       23.4%
  ---------------------------------------- -------------

**Abbreviations:** NYHA, New York Heart Association.

Treatment of patients with CHF in Japan
---------------------------------------

Treatments with angiotensin converting enzyme inhibitors (ACEI), angiotensin II receptor blockers (ARB), or β-blockers are recommended to improve prognosis and quality of life for patients with CHF ([@b9]). However it has previously been reported that such evidence-based treatments might not be sufficiently used in patients who should have had benefits of such medications ([@b13]). The overall usage rate of ACEI/ARB or β-blocker in patients enrolled in the CHART-1 study was 70% and 28%, respectively ([Figure 4](#fig4){ref-type="fig"}). The penetration rate of these medications was relatively lower in female patients, elderly patients, and those with valvular heart disease or preserved LVEF, and this trend was more evident for the treatment with β-blocker than ACEI/ARB ([Figure 4](#fig4){ref-type="fig"}). These results suggest that future clinical trials are still necessary for such minorities who have not usually been enrolled in major randomized treatment trials for CHF.

![Prevalence of the use of renin-angiotensin inhibitors and β-blockers in the CHART-1 study. Copyright © 2007. Reproduced with permission from [@b22]. The CHART Study (Japanese). *Naika*, 99:410--14.\
**Abbreviations:** ACEI, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; NICM, non-ischemic cardiomyopathy; LVH, left ventricular hypertrophy; VHD, valvular heart disease.](vhrm0401-103-04){#fig4}

Clinical outcomes of Japanese patients with CHF
-----------------------------------------------

[Figure 5](#fig5){ref-type="fig"} showed survival curves of placebo groups in randomized treatment trials for CHF performed in Western countries, superimposed with the result obtained in our CHART-1 study with Japanese CHF patients. One-year all-cause mortality of patients with mild-moderate CHF (NYHA II--IV and LVEF ≤40%) or moderate-severe CHF (NYHA III--IV and LVEF ≤35%) was 13% and 21%, respectively. Importantly, as is evident in [Figure 5](#fig5){ref-type="fig"}, the prognosis of Japanese patients with CHF was equally poor compared with Western CHF patients. Since the Japanese society is aging rapidly, a sharp increase in the number of CHF patients will be inevitable in the near future in Japan, as CHF is a disease of the elderly. [Figure 6](#fig6){ref-type="fig"} shows the event rate in CHF patients based on age at the entry, demonstrating that elderly Japanese patients with CHF had an increased incidence of cardiac death and a combination of cardiac death and admission due to congestive CHF. This is because elderly CHF patients have a higher rate of combined risk factors, such as anemia, chronic kidney disease, hypertension, and atrial fibrillation. Appropriate prevention strategies against the development and progression of CHF should be undertaken in Japan.

![Comparison of the prognosis of patients with CHF between Western clinical trials and the CHART-1 study. Copyright © 2007. Reproduced with permission from [@b22]. The CHART Study (Japanese). *Naika*, 99:410--14.\
**Abbreviations:** HYHA, New York Heart Association.](vhrm0401-103-05){#fig5}

![Prognosis of elderly patients with CHF in the CHART-1 study. Copyright © 2007. Reproduced with permission from [@b22]. The CHART Study (Japanese). *Naika*, 99:410--14.\
**Abbreviations:** CHF, congestive heart failure.](vhrm0401-103-06){#fig6}

Major CHF treatment trials in Japan
-----------------------------------

There are 2 published randomized treatment trials for CHF patients in Japan ([Table 3](#tbl3){ref-type="table"}). The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial enrolled 174 patients with mild to moderate CHF to seek for the efficacy and optimum dose of carvedilol, with 3 treatment arms, including placebo, 5 and 20 mg of the β-blocker in daily dose ([@b8]). During the 24--48 weeks of the treatment period, carvedilol achieved dose-related improvement of the rate of death or cardiovascular hospitalization to 25%, 9%, and 5% in the placebo, 5 mg, and 20 mg group, respectively (p = 0.002). The Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) study investigated the efficacy of candesartan (8 mg once daily) in comparison with the placebo in 305 patients with symptomatic CHF ([@b14]). During the 6-month follow-up period, fatal cardiovascular events occurred in 2 patients in each treatment group and the incidence of progression of CHF was 7% and 22% in the candesartan and the placebo group, respectively (p = 0.0004).

###### 

3 Multicenter randomized clinlical trials for patients with chronic heart failure in Japan

  Trial \[Reference\]     Design   Age, years (Mean)   Comparison                                 Total enrollment   HF stage NYHA   Study start Expected completion   Mean follow-up   Primary outcome \*Published main outcome                  Status
  ----------------------- -------- ------------------- ------------------------------------------ ------------------ --------------- --------------------------------- ---------------- --------------------------------------------------------- ------------
  MUCHA Trial \[[@b8]\]   RDBPC    20--79 (60)         Carvedilol 5 mg Carvedilol 20 mg Placebo   174                C-D II-III                                        24--48 weeks     Dose-related improvement of HF with carvedilol\*          Published
  ARCH-J \[[@b14]\]       RDBPC    ≥20 (64)            Candesartan Placebo                        305                C-D II-III                                        6 months         Slowing progression of HF with candesartan\*              Published
  J-CHF                   PROBE    20--79              Carvedilol; 2.5 mg, 5 mg, or 20 mg         480 (exp.)         C-D II-III      Jul 2003 Dec 2009                                  Cardiovascular mortality Hospitalization for HF           Recruiting
  J-DHF                   PROBE    ≥20                 Carvedilol Control                         800 (exp.)         C-D             May 2004 Mar 2011                                  Cardiovascular mortality Hospitalization for HF           Recruiting
  SUPPORT Trial           PROBE    20--79              Olmesartan Standard therapy                1000 (exp.)        C-D II-IV       Nov 2006 Sep 2011                                  Combination of mortality/AMI/Stroke/admission due to HF   Recruiting
  PEARL Study             RO       20--79              Pitavastatin Control                       500 (exp.)         C-D II-III      Jul 2006 Jul 2010                                  Cardiac mortality Hospitalization for HF                  Recruiting
  J-MELODIC               PROBE    ≥20                 Furosemide Azosemide                       300 (exp.)         C-D II-III      Jun 2006 Mar 2010                                  Cardiovascular mortality Hospitalization for HF           Recruiting
  J-HOMECARE              RO       N/A                 Education/counseling Control               300 (exp.)         C-D             Dec 2006 Dec 2008                                  Mortality Readmission for HF                              Recruiting

Data are retrieved from published papers or the UMIN Clinical Trials Registry (<http://www.umin.ac.jp/ctr/index-j.htm>)/ClinicalTrials.gov (<http://clinicaltrials.gov/>).

**Abbreviations:** RDBPC, randomized double-blind placebo-controlled design; NYHA, New York Heart Association; HF, heart failure; PROBE, prospective randomized open blinded end-point design; exp., expected; AMI, acute myocardial infarction, RO; randomized open-label design.

We have recently initiated a large outcome study with olmesartan in CHF patients, termed The Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients with Stable Heart Failure Using Olmesartan (SUPPORT trial), which is currently the largest outcome study in Japan ([Table 3](#tbl3){ref-type="table"}). The purpose of our SUPPORT trial is to examine whether an ARB, olmesartan, in addition to conventional treatment, reduces the mortality and morbidity of hypertensive patients with stable CHF. The primary endpoint is a combined event of all-cause death, nonfatal acute myocardial infarction, nonfatal stroke, and hospital admission due to congestive heart failure. We also aim to evaluate the beneficial effect of olmesartan on the progression of metabolic syndrome. The entry of patients was started in November 2007, and the results of the study will be obtained by the end of 2011.

There are 5 other small outcome trials that are currently in progress in Japan ([Table 3](#tbl3){ref-type="table"}). The Assessment of Beta-Blocker Treatment in Japanese Patients with Chronic Heart Failure (J-CHF) and the Japanese Diastolic Heart Failure Study (J-DHF) are investigating the effects of carvedilol in patients with systolic CHF and those with diastolic CHF, respectively. Another objective of J-CHF is to determine the optimum dose of carvedilol and to elucidate the differences in clinical characteristics between responders and nonresponders to the β-blocker. The Pitavastatin Heart Failure Study (PEARL study) is designed to evaluate the efficacy of pitavastatin for CHF with mild hypercholesterolemia. The Japanese Multicenter Evaluation of Long- versus short-acting Diuretics in Congestive Heart Failure (J-MELODIC) is designed to compare the effects of furosemide and azosemide in patients with CHF and to test the hypothesis that long-acting diuretics are superior to short-acting ones in those patients. The Japanese Heart Failure Outpatients Disease Management and Cardiac Evaluation Study (J-HOMECARE) was designed to evaluate the benefit of disease management program for prognosis, psychological status and quality of life of patients with CHF.

There are 2 large trials that have investigated the role of valsartan in Japanese patients with cardiovascular disease including CHF ([Table 4](#tbl4){ref-type="table"}). The Japanese Investigation of Kinetic Evaluation in Hypertensive Event and Remodeling Treatment (JIKEI-HEART) Study was designed to investigate whether concomitant treatment with valsartan in addition to conventional treatment improves the prognosis of Japanese patients with hypertension, ischemic heart disease, or congestive heart failure. The results of this study have recently been published ([@b16]). After a median follow-up period of 3.1 years, the incidences of stroke, transient ischemic attack, angina pectoris, and CHF were significantly lower in patients treated with valsartan compared with those with the conventional treatment. However, the benefit of the add-on valsartan treatment in a sub-population with CHF, which accounted for 11% of the total population, has not been published yet. The Add-on Effects of Valsartan on Morbi-Mortality (KYOTO-HEART) study was designed to assess the add-on effect of valsartan on the conventional treatment in terms of the morbidity and mortality in Japanese hypertensive patients with high risks of cardiovascular diseases including CHF ([Table 4](#tbl4){ref-type="table"}).

###### 

Multicenter randomized clinlical trials for patients with cardiovascular risks including CHF in Japan

  Trial \[Reference\]            Design   Study population                                                     Age, years (Mean)   Comparison                   Total enrollment   Study start Expected completion   Duration    Primary outcome \*Published main outcome                          Status
  ------------------------------ -------- -------------------------------------------------------------------- ------------------- ---------------------------- ------------------ --------------------------------- ----------- ----------------------------------------------------------------- ------------
  JIKEI-Heart Study \[[@b16]\]   PROBE    Hypertension coronary disease heart failure                          20--79 (65)         Valsartan Standard therapy   3081                                                 3.1 years   Prevention of cardiovascular events with additional valsartan\*   Published
  KYOTO-HEART Study              PROBE    Hypertension with one or more risk factors including heart failure   20--79              Valsartan Standard therapy   3000 (exp.)        Jan 2004 Oct 2007                             Combination of stroke/AMI/CHF etc.                                Recruiting

Data are retrieved from published papers or the UMIN Clinical Trials Registry (<http://www.umin.ac.jp/ctr/index-j.htm>) / ClinicalTrials.gov (<http://clinicaltrials.gov/>).

**Abbreviations:** PROBE, prospective randomized open blinded end-point design; exp., expected; AMI, acute myocardial infarction; CHF, congestive heart failure.

Many of the randomized clinical trials performed in Japan utilize the prospective randomized open blinded endpoint (PROBE) design, as an alternative to the randomized double-blind placebo-controlled design ([Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}). This is mainly because the PROBE study tends to be more cost effective and its open-labeled medication may minimize ethical considerations ([@b7]).

Racial difference in morbidity and mortality due to cardiovascular diseases
---------------------------------------------------------------------------

Several researchers have suggested that cardiovascular risk factors have different prognostic impact among different populations. The Seven Countries Study Research Group showed a substantial heterogeneity among populations in terms of the death rate due to coronary artery disease, even at a similar level of blood pressure ([@b28]). The proportion of deaths attributable to cardiovascular disease has also been reported to vary among different cohorts even at the similar serum cholesterol level. The long-term follow-up for 25 years for 12,763 men in 16 cohorts in Europe, the United States, and Japan showed that the risk factors of cardiovascular disease, such as insufficient physical activity and high serum cholesterol level, were not significantly associated with all-cause death in several countries including Japan ([@b15]). Since these differences cannot be explained by other baseline characteristics, smoking habits, or genetic difference, environmental and/or behavioral factors may play an important role in the development of cardiovascular diseases. The Ni-Hon-San Study, which compared cardiovascular disease rates and risk factors in Japanese men living in Japan, Hawaii, and California, showed that the mortality rate due to coronary artery disease was lowest in Japanese men living in Japan, whereas it was highest in those living in California ([@b2]). Racial differences may also influence the effect of medical treatment for CHF. Several studies demonstrated that genetic polymorphisms and/or a difference in β1-receptor sensitivity, which are frequently observed in the Japanese population, might change the pharmacokinetics or the clinical effect of medical drugs, such as ACEI and β-blockers ([@b11]; [@b31]; [@b18]).

Future direction for the management of CHF in Japan
===================================================

CHF is a slowly progressive disease from stage A to stage D unless appropriately treated as described in the ACC/AHA guidelines ([@b9]). The strategy to manage CHF has been changing recently from treatment to prevention ([@b1]). Japanese CHF patients have several different profiles compared with Western CHF patients as follows; (*a*) the prevalence of CHF of ischemic origin is lower, (*b*) the percentage of elderly population is remarkably high, and (*c*) the penetration rate of evidence-based medicine, such as ACEI/ARB or β-blockers, is not sufficiently high yet. The current situation of the management of CHF in Japan is probably caused by the fact that the number of randomized treatment trials for Japanese patients is not enough yet. Given the expected future increase in Japanese patients with CHF, effective prevention strategy is necessary. Our on-going CHART-2 and SUPPORT studies will enable us to obtain effective strategies to improve the management of CHF in Japan.

Conclusions
===========

The prevalence of CHF will rapidly increase in the next decades in many industrialized countries, including Japan. Large cohort studies with CHF patients are useful for risk stratification and determination of preventive measures for the disorder. Large-scale, randomized treatment trials also are needed, especially in Japan, in order to obtain further evidence to improve the management of patients with CHF.

Active investigators of the CHART studies were described in the paper previously published ([@b20]) and at the website of the Tohoku Heart Failure Association (see <http://tohoku.cardiovascular-medicine.jp>). The CHART-1 study was supported by the research grants from the Ministry of Health, Labor and Welfare and Gonryo Medical Foundation. We are grateful for the assistance of research nurses who are working at the Tohoku Heart Failure Association; Mika Matsuki, Shizuka Osaki, Kiriko Yukishita, Yuuko Kidoguchi, Miho Hotta, Haruka Kohno, and Keiko Nishiura.
